Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers

Open-Label, Active Controlled, Single-Center, Phase 1 Study to Determine the Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03647982

Enrollment

Registered

2018-08-27

Start date

2018-03-20

Completion date

2018-11-20

Last updated

2019-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anhidrotic Area, Hyperhidrosis

Brief summary

To determine the anhidrotic area and safety of MEDITOXIN

Interventions

DRUGMeditoxin

injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses

DRUGBotox

injection of Botox into the intradermal of each contralateral upper back in equal doses

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

MALE

Age

20 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Male adults aged between 20 and 45 years

Exclusion criteria

* Subjects not appropriate for participating in this study according to the investigator's opinion

Design outcomes

Primary

Measure	Time frame	Description
anhidrotic area	week 4	After the ninhydrin sweat test, measure the area of the unstained area

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026